NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NASDAQ NURO opened at $4.42 on Monday. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73. The stock has a market cap of $9.05 million, a PE ratio of -0.96 and a beta of 2.18. The firm has a 50-day simple moving average of $4.14 and a 200 day simple moving average of $4.02.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix as of its most recent filing with the Securities & Exchange Commission. 19.40% of the stock is owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.